Search

Your search keyword '"Zamboglou C"' showing total 272 results
Start Over Author "Zamboglou C"
272 results on '"Zamboglou C"'

1. The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy: a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO)

Author

Zamboglou, C., Aebersold, D. M., Albrecht, C., Boehmer, D., Ganswindt, U., Schmidt-Hegemann, N.-S., Hoecht, S., Hölscher, T., Koerber, S. A., Mueller, A.-C., Niehoff, P., Peeken, J. C., Pinkawa, M., Polat, B., Spohn, S. K. B., Wolf, F., Zips, D., and Wiegel, T.

Published
2024
Full Text
View/download PDF

2. The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on 18F-PSMA-1007 PET

Author

Holzschuh, Julius C., Mix, Michael, Freitag, Martin T., Hölscher, Tobias, Braune, Anja, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K. B., Fechter, Tobias, Kuhn, Dejan, Gratzke, Christian, Grosu, Radu, Grosu, Anca-Ligia, and Zamboglou, C.

Published
2024
Full Text
View/download PDF

3. Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)

Author

Koerber, S. A., Höcht, S., Aebersold, D., Albrecht, C., Boehmer, D., Ganswindt, U., Schmidt-Hegemann, N.-S., Hölscher, T., Mueller, A.-C., Niehoff, P., Peeken, J. C., Pinkawa, M., Polat, B., Spohn, S. K. B., Wolf, F., Zamboglou, C., Zips, D., and Wiegel, T.

Published
2024
Full Text
View/download PDF

4. Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

Author

Spohn, S. K. B., Adebahr, S., Huber, M., Jenkner, C., Wiehle, R., Nagavci, B., Schmucker, C., Carl, E. G., Chen, R. C., Weber, W. A., Mix, M., Rühle, A., Sprave, T., Nicolay, N. H., Gratzke, C., Benndorf, M., Wiegel, T., Weis, J., Baltas, D., Grosu, A. L., and Zamboglou, C.

Published
2022
Full Text
View/download PDF

5. The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on 18F-PSMA-1007 PET.

Author

Holzschuh, Julius C., Mix, Michael, Freitag, Martin T., Hölscher, Tobias, Braune, Anja, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K. B., Fechter, Tobias, Kuhn, Dejan, Gratzke, Christian, Grosu, Radu, Grosu, Anca-Ligia, and Zamboglou, C.

Subjects
CONVOLUTIONAL neural networks, VOLUMETRIC analysis, POSITRON emission tomography, PROSTATE cancer, STATISTICAL significance
Abstract

Purpose: Convolutional Neural Networks (CNNs) have emerged as transformative tools in the field of radiation oncology, significantly advancing the precision of contouring practices. However, the adaptability of these algorithms across diverse scanners, institutions, and imaging protocols remains a considerable obstacle. This study aims to investigate the effects of incorporating institution-specific datasets into the training regimen of CNNs to assess their generalization ability in real-world clinical environments. Focusing on a data-centric analysis, the influence of varying multi- and single center training approaches on algorithm performance is conducted. Methods: nnU-Net is trained using a dataset comprising 161 18F-PSMA-1007 PET images collected from four distinct institutions (Freiburg: n = 96, Munich: n = 19, Cyprus: n = 32, Dresden: n = 14). The dataset is partitioned such that data from each center are systematically excluded from training and used solely for testing to assess the model's generalizability and adaptability to data from unfamiliar sources. Performance is compared through a 5-Fold Cross-Validation, providing a detailed comparison between models trained on datasets from single centers to those trained on aggregated multi-center datasets. Dice Similarity Score, Hausdorff distance and volumetric analysis are used as primary evaluation metrics. Results: The mixed training approach yielded a median DSC of 0.76 (IQR: 0.64–0.84) in a five-fold cross-validation, showing no significant differences (p = 0.18) compared to models trained with data exclusion from each center, which performed with a median DSC of 0.74 (IQR: 0.56–0.86). Significant performance improvements regarding multi-center training were observed for the Dresden cohort (multi-center median DSC 0.71, IQR: 0.58–0.80 vs. single-center 0.68, IQR: 0.50–0.80, p < 0.001) and Cyprus cohort (multi-center 0.74, IQR: 0.62–0.83 vs. single-center 0.72, IQR: 0.54–0.82, p < 0.01). While Munich and Freiburg also showed performance improvements with multi-center training, results showed no statistical significance (Munich: multi-center DSC 0.74, IQR: 0.60–0.80 vs. single-center 0.72, IQR: 0.59–0.82, p > 0.05; Freiburg: multi-center 0.78, IQR: 0.53–0.87 vs. single-center 0.71, IQR: 0.53–0.83, p = 0.23). Conclusion: CNNs trained for auto contouring intraprostatic GTV in 18F-PSMA-1007 PET on a diverse dataset from multiple centers mostly generalize well to unseen data from other centers. Training on a multicentric dataset can improve performance compared to training exclusively with a single-center dataset regarding intraprostatic 18F-PSMA-1007 PET GTV segmentation. The segmentation performance of the same CNN can vary depending on the dataset employed for training and testing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. What MRI Sequences are Necessary for Automated Neural Network-Based Metastasis Segmentation ― An Ablation Study

Author

Buchner, J.A., primary, Kofler, F., additional, Mayinger, M.C., additional, Brunner, T.B., additional, Wittig, A., additional, Menze, B., additional, Zimmer, C., additional, Meyer, B., additional, Guckenberger, M., additional, Andratschke, N., additional, Shafie, R. El, additional, Rogers, S., additional, Schulze, K., additional, Blanck, O., additional, Zamboglou, C., additional, Grosu, A., additional, Combs, S.E., additional, Bernhardt, D., additional, Wiestler, B., additional, and Peeken, J.C., additional

Published
2023
Full Text
View/download PDF

7. Toxicity and Patient Reported Quality of Life after PSMA-PET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial

Author

Spohn, S.K.B., primary, Gainey, M., additional, Kamps, M., additional, Jilg, C.A., additional, Gratzke, C., additional, Sigle, A., additional, Mix, M., additional, Ruf, J., additional, Bürkle, S., additional, Sprave, T., additional, Wiehle, R., additional, Serpa, M., additional, Benndorf, M., additional, Zschaeck, S., additional, Ghadjar, P., additional, Baltas, D., additional, Kirste, S., additional, Zamboglou, C., additional, and Grosu, A., additional

Published
2023
Full Text
View/download PDF

8. PD-0567 CT-based radiomic signatures to predict biochemical recurrence after salvage radiotherapy

Author

Spohn, S., primary, Schmidt-Hegemann, N., additional, Ruf, J., additional, Mix, M., additional, Benndorf, M., additional, Makowski, M.R., additional, Kirste, S., additional, Vogel, M.M., additional, Gschwend, J.E., additional, Gratzke, C., additional, Stief, C., additional, Löck, S., additional, Zwanenburrg, A., additional, Trapp, C., additional, Galitsnaya, P., additional, Nekolla, S.G., additional, Belka, C., additional, Combs, S.E., additional, Eiber, M., additional, Unterrainer, L., additional, Unterrainer, M., additional, Bartenstein, P., additional, Grosu, A.L., additional, Zamboglou, C., additional, and Peeken, J.C., additional

Published
2023
Full Text
View/download PDF

9. MO-0221 Intraprostatic GTV delineation in 18F-PSMA-PET Images for Patients with Primary PCa using a CNN

Author

Holzschuh, J., primary, Mix, M., additional, Ruf, J., additional, Hölscher, T., additional, Kotzerke, J., additional, Vrachimis, A., additional, Ilhan, H., additional, Spohn, S.K., additional, Fechter, T., additional, Kostyszyn, D., additional, Bronsert, P., additional, Gratzke, C., additional, Grosu, R., additional, Kamran, S.C., additional, Heidari, P., additional, Ng, T.S., additional, Könik, A., additional, Grosu, A., additional, and Zamboglou, C., additional

Published
2023
Full Text
View/download PDF

10. OC-0435 Multi-institutional nomogram for PSMA-PET based salvage radiotherapy in recurrent prostate cancer

Author

Zamboglou, C., primary, Ferentinos, K., additional, Arnoux, A., additional, Janbain, A., additional, Strouthose, I., additional, Farolfi, A., additional, Koerber, S., additional, Peeken, J., additional, Vogel, M., additional, Vrachimis, A., additional, Spohn, S.K.B., additional, Shelan, M., additional, Grosu, A., additional, Kroeze, S., additional, Guckenberger, M., additional, Fanti, S.F., additional, Belka, C., additional, Hruby, G., additional, Scharl, S., additional, Wiegel, T., additional, Henkenberens, C., additional, Emmett, L., additional, and Schmidt-Hegemann, N.S., additional

Published
2023
Full Text
View/download PDF

11. PD-0174 Radiomics-based prediction of local control of brain metastases after resection and radiotherapy

Author

Buchner, J.A., primary, Kofler, F., additional, Mayinger, M., additional, Christ, S.M., additional, Brunner, T.B., additional, Wittig, A., additional, Menze, B., additional, Zimmer, C., additional, Meyer, B., additional, Guckenberger, M., additional, Andratschke, N., additional, El Shafie, R.A., additional, Debus, J., additional, Rogers, S., additional, Riesterer, O., additional, Schulze, K., additional, Feldmann, H.J., additional, Blanck, O., additional, Zamboglou, C., additional, Ferentinos, K., additional, Wolff, R., additional, Eitz, K.A., additional, Combs, S.E., additional, Bernhardt, D., additional, Wiestler, B., additional, and Peeken, J.C., additional

Published
2023
Full Text
View/download PDF

14. Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus.

Author

Spohn, S.K.B., Draulans, C., Kishan, A.U., Spratt, D., Ross, A., Maurer, T., Tilki, D., Berlin, A., Blanchard, P., Collins, S., Bronsert, P., Chen, Ronald, Pra, A.D., Meerleer, G. de, Eade, T., Haustermans, K., Hölscher, T., Höcht, S., Ghadjar, P., Davicioni, E., Heck, M., Kerkmeijer, L.G.W., Kirste, S., Tselis, N., Tran, P.T., Pinkawa, M., Pommier, P., Deltas, C., Schmidt-Hegemann, N.S., Wiegel, T., Zilli, T., Tree, A.C., Qiu, X., Murthy, V., Epstein, J.I., Graztke, C., Gao, X., Grosu, A.L., Kamran, S.C., Zamboglou, C., Spohn, S.K.B., Draulans, C., Kishan, A.U., Spratt, D., Ross, A., Maurer, T., Tilki, D., Berlin, A., Blanchard, P., Collins, S., Bronsert, P., Chen, Ronald, Pra, A.D., Meerleer, G. de, Eade, T., Haustermans, K., Hölscher, T., Höcht, S., Ghadjar, P., Davicioni, E., Heck, M., Kerkmeijer, L.G.W., Kirste, S., Tselis, N., Tran, P.T., Pinkawa, M., Pommier, P., Deltas, C., Schmidt-Hegemann, N.S., Wiegel, T., Zilli, T., Tree, A.C., Qiu, X., Murthy, V., Epstein, J.I., Graztke, C., Gao, X., Grosu, A.L., Kamran, S.C., and Zamboglou, C.

Abstract

Item does not contain fulltext, Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ≥75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and

Published
2023

15. Radiotherapy Versus Chemoradiation in Elderly Head-and-Neck Squamous Cell Carcinoma Patients – A Retrospective International Multicenter Study

Author

Ruhle, A., primary, Marschner, S., additional, Fabian, A., additional, Senger, C., additional, Kraft, J., additional, von der Grün, J., additional, Domschikowski, J., additional, Bickel, A., additional, Altay-Langguth, A., additional, Lewitzki, V., additional, Ferentinos, K., additional, Zamboglou, C., additional, Guckenberger, M., additional, Budach, V., additional, Belka, C., additional, Grosu, A.L., additional, Mayer, A., additional, Balermpas, P., additional, Stromberger, C., additional, and Nicolay, N.H., additional

Published
2022
Full Text
View/download PDF

16. The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis

Author

Spohn, S.K.B., primary, Farolfi, A., additional, Schandeler, S., additional, Vogel, M.M., additional, Ruf, J., additional, Mix, M., additional, Kirste, S., additional, Ceci, F., additional, Fanti, S., additional, Lanzafame, H., additional, Gratzke, C., additional, Sigle, A., additional, Combs, S.E., additional, Bernhardt, D., additional, Gschwend, J.E., additional, Buchner, J.A., additional, Trapp, C., additional, Belka, C., additional, Bartenstein, P., additional, Eiber, M., additional, Nekolla, S., additional, Schiller, K., additional, Grosu, A., additional, Schmidt-Hegemann, N.S., additional, Zamboglou, C., additional, and Peeken, J.C., additional

Published
2022
Full Text
View/download PDF

19. Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy

Author

Zamboglou, C., Strouthos, I., Sahlmann, J., Farolfi, A., Serani, F., Medici, F., Cavallini, L., Morganti, A.G., Trapp, C., Koerber, S.A., Peeken, J.C., Vogel, M.M.E., Schiller, K., Combs, S.E., Eiber, M., Vrachimis, A., Ferentinos, K., Spohn, S.K.B., Kirste, S., Gratzke, C., Ruf, J., Grosu, A.-., Ceci, F., Fendler, W.P., Miksch, J., Kroeze, S., Guckenberger, M., Lanzafame, H., Fanti, S., Hruby, G., Wiegel, T., Emmett, L., Schmidt-Hegemann, N.S., and Henkenberens, C.

Subjects
Male, Prostatectomy, Salvage Therapy, Prostate, Prostatic Neoplasms, Androgen Antagonists, Gallium Radioisotopes, Neoplasm Recurrence, Local, Settore MED/36 - Diagnostica per Immagini e Radioterapia, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Humans, Neoplasm Recurrence, Local, Retrospective Studies
Published
2022

20. Correction to: Value of PET imaging for radiation therapy

Author

Lapa, C., Nestle, U., Albert, N. L., Baues, C., Beer, A., Buck, A., Budach, V., Bütof, R., Combs, S. E., Derlin, T., Eiber, M., Fendler, W. P., Furth, C., Gani, C., Gkika, E., Grosu, A.-L., Henkenberens, C., Ilhan, H., Löck, S., Marnitz-Schulze, S., Miederer, M., Mix, M., Nicolay, N. H., Niyazi, M., Pöttgen, C., Todica, A. S., Weber, W., Wegen, S., Wiegel, T., Zamboglou, C., Zips, D., Zöphel, K., Zschaeck, S., Thorwarth, D., (0000-0001-9550-9050) Troost, E. G. C., Lapa, C., Nestle, U., Albert, N. L., Baues, C., Beer, A., Buck, A., Budach, V., Bütof, R., Combs, S. E., Derlin, T., Eiber, M., Fendler, W. P., Furth, C., Gani, C., Gkika, E., Grosu, A.-L., Henkenberens, C., Ilhan, H., Löck, S., Marnitz-Schulze, S., Miederer, M., Mix, M., Nicolay, N. H., Niyazi, M., Pöttgen, C., Todica, A. S., Weber, W., Wegen, S., Wiegel, T., Zamboglou, C., Zips, D., Zöphel, K., Zschaeck, S., Thorwarth, D., and (0000-0001-9550-9050) Troost, E. G. C.

Abstract

Correction to: Strahlenther Onkol 2021 https://doi.org/10.1007/s00066-021-01812-2

Published
2022

24. PO-1414 Results of a concept-development for a phase III trial on radiotherapy in primary prostate cancer

Author

Spohn, S., primary, Adebahr, S., additional, Huber, M., additional, Jenkner, C., additional, Wiehle, R., additional, Nagavci, B., additional, Schmucker, C., additional, Carl, E., additional, Chen, R., additional, Weber, W., additional, Mix, M., additional, Rühle, A., additional, Nicolay, N., additional, Gratzke, C., additional, Benndorf, M., additional, Wiegel, T., additional, Weis, J., additional, Baltas, D., additional, Zamboglou, C., additional, and Grosu, A., additional

Published
2022
Full Text
View/download PDF

28. Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis

Author

Zamboglou, C., primary, Schmidt-Hegemann, N.S., additional, Emmett, L., additional, Strouthos, I., additional, Ferentinos, K., additional, Serani, F., additional, Farolfi, A., additional, Fanti, S., additional, Federica, M., additional, Lanzafame, H., additional, Kirste, S., additional, Ruf, J., additional, Vrachimis, A., additional, Ceci, F., additional, Grosu, A.L., additional, and Henkenberens, C., additional

Published
2021
Full Text
View/download PDF

31. PD-0874 Impact of dose and prescription method in SBRT of NSCLC. A pooled analysis of 2 prospective trials.

Author

Gkika, E., primary, Adebahr, S., additional, Radicioni, G., additional, Exner, J., additional, Haehl, E., additional, Spohn, S., additional, Rühle, A., additional, Zamboglou, C., additional, Nicolay, N., additional, Sprave, T., additional, Wiehle, R., additional, Baltas, D., additional, Nestle, U., additional, and Grosu, A., additional

Published
2021
Full Text
View/download PDF

32. PO-1329 Longterm Biochemical Recurrence-Free Survival after PSMA-PET/CT–Based Salvage Radiotherapy

Author

Adebahr, S., primary, Zamboglou, C., additional, Ruf, J., additional, Gratzke, C., additional, Kirste, S., additional, Spohn, S., additional, Stief, C., additional, Bartenstein, P., additional, Belka, C., additional, Li, M., additional, Trapp, C., additional, Rogowski, P., additional, Grosu, A., additional, and Schmidt-Hegemann, N., additional

Published
2021
Full Text
View/download PDF

35. PH-0659 Metastasis-free survival after salvage radiotherapy in post-operative prostate cancer patients in the PSMA PET/CT era – a bi-institutional, retrospective analysis

Author

Schmidt-Hegemann, N., primary, Grosu, A.L., additional, Ruf, J., additional, Gratzke, C., additional, Adebahr, S., additional, Stief, C., additional, Bartenstein, P., additional, Belka, C., additional, Li, M., additional, Trapp, C., additional, Rogowski, P., additional, and Zamboglou, C., additional

Published
2021
Full Text
View/download PDF

38. FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy

Author

Carles M, Fechter T, Radicioni G, Schimek-Jasch T, Adebahr S, Zamboglou C, Nicolay NH, Martí-Bonmatí L, Nestle U, Grosu AL, Baltas D, Mix M, and Gkika E

Subjects
FDG monitoring and retrospectively gated 4D PET/CT, PET radiomics, lung cancer
Abstract

The aim of this study is to identify clinically relevant image feature (IF) changes during chemoradiation and evaluate their efficacy in predicting treatment response. Patients with non-small-cell lung cancer (NSCLC) were enrolled in two prospective trials (STRIPE, PET-Plan). We evaluated 48 patients who underwent static (3D) and retrospectively-respiratory-gated 4D PET/CT scans before treatment and a 3D scan during or after treatment. Our proposed method rejects IF changes due to intrinsic variability. The IF variability observed across 4D PET is employed as a patient individualized normalization factor to emphasize statistically relevant IF changes during treatment. Predictions of overall survival (OS), local recurrence (LR) and distant metastasis (DM) were evaluated. From 135 IFs, only 17 satisfied the required criteria of being normally distributed across 4D PET and robust between 3D and 4D images. Changes during treatment in the area-under-the-curve of the cumulative standard-uptake-value histogram (d AUC CSH ) within primary tumor discriminated (AUC = 0.87, Specificity = 0.78) patients with and without LR. The resulted prognostic model was validated with a different segmentation method (AUC = 0.83) and in a different patient cohort (AUC = 0.63). The quantification of tumor FDG heterogeneity by d AUC CSH during chemoradiation correlated with the incidence of local recurrence and might be recommended for monitoring treatment response in patients with NSCLC.

Published
2021

39. Innovative radiation oncology Together – Precise, Personalized, Human: Vision 2030 for radiotherapy & radiation oncology in Germany

Author

Krug, D., Hecht, M., Ebert, N., Maurer, M., Fleischmann, D.F., Fokas, E., Straube, C., Nicolay, N.H., Hörner-Rieber, J., Schmitt, D., von Neubeck, C., Zamboglou, C., Sperk, E., Kaul, D., Hess-Rieger, J., Corradini, S., Seidel, C., Gani, C., Baues, C., Frey, B., Blanck, O., Gauer, T., and Niyazi, M.

Subjects
Career Development, Image Guidance, Precision Oncology, Radiation Therapy, Vision Development
Abstract

Purpose: Scientific and clinical achievements in radiation, medical, and surgical oncology are changing the landscape of interdisciplinary oncology. The German Society for Radiation Oncology (DEGRO) working group of young clinicians and scientists (yDEGRO) and the DEGRO representation of associate and full professors (AKRO) are aware of the essential role of radiation oncology in multidisciplinary treatment approaches. Together, yDEGRO and AKRO endorsed developing aGerman radiotherapy& radiation oncology vision 2030 to address future challenges in patient care, research, and education. The vision 2030 aims to identify priorities and goals for the next decade in the field of radiation oncology. Methods: The vision development comprised three phases. During the first phase, areas of interest, objectives, and the process of vision development were defined jointly by the yDEGRO, AKRO, and the DEGRO board. In the second phase, aone-day strategy retreat was held to develop AKRO and yDEGRO representatives’ final vision from medicine, biology, and physics. The third phase was dedicated to vision interpretation and program development by yDEGRO representatives. Results: The strategy retreat’s development process resulted in conception of the final vision “Innovative radiation oncology Together– Precise, Personalized, Human.” The first term “Innovative radiation oncology” comprises the promotion of preclinical research and clinical trials and highlights the development of anational committee for strategic development in radiation oncology research. The term “together” underpins collaborations within radiation oncology departments as well as with other partners in the clinical and scientific setting. “Precise” mainly covers technological precision in radiotherapy as well as targeted oncologic therapeutics. “Personalized” emphasizes biology-directed individualization of radiation treatment. Finally, “Human” underlines the patient-centered approach and points towards the need for individual longer-term career curricula for clinicians and researchers in the field. Conclusion: The vision 2030 balances the ambition of physical, technological, and biological innovation as well as acomprehensive, patient-centered, and collaborative approach towards radiotherapy& radiation oncology in Germany.

Published
2021

40. F-18-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy

Author

Carles, M, Fechter, T, Grosu, AL, Sorensen, A, Thomann, B, Stoian, RG, Wiedenmann, N, Ruhle, A, Zamboglou, C, Ruf, J, Marti-Bonmati, L, Baltas, D, Mix, M, and Nicolay, NH

Subjects
F-18-FMISO-PET, hypoxia, head-and-neck squamous cell carcinoma and radiomics, radiotherapy response monitoring
Abstract

Simple Summary In this study, we monitored FMISO-hypoxia during chemo-radiotherapy (CRT) in head-and-neck cancer patients and we aimed to develop a radiomics model for prediction of treatment outcome. The protocol for the prospective patient cohort (N = 35) involved FMISO-PET/CT imaging at three time-points during treatment (weeks 0, 2 and 5). FMISO-hypoxia monitoring was quantified in terms of variations in the size, in the location and in the radiomics features (delta radiomics) of the hypoxia subvolume within the tumor. Local recurrence, distant metastasis, overall survival and progression free survival were employed for the characterization of CRT outcome. Tumor hypoxia is associated with radiation resistance and can be longitudinally monitored by F-18-fluoromisonidazole (F-18-FMISO)-PET/CT. Our study aimed at evaluating radiomics dynamics of F-18-FMISO-hypoxia imaging during chemo-radiotherapy (CRT) as predictors for treatment outcome in head-and-neck squamous cell carcinoma (HNSCC) patients. We prospectively recruited 35 HNSCC patients undergoing definitive CRT and longitudinal F-18-FMISO-PET/CT scans at weeks 0, 2 and 5 (W0/W2/W5). Patients were classified based on peritherapeutic variations of the hypoxic sub-volume (HSV) size (increasing/stable/decreasing) and location (geographically-static/geographically-dynamic) by a new objective classification parameter (CP) accounting for spatial overlap. Additionally, 130 radiomic features (RF) were extracted from HSV at W0, and their variations during CRT were quantified by relative deviations ( increment (RF)). Prediction of treatment outcome was considered statistically relevant after being corrected for multiple testing and confirmed for the two F-18-FMISO-PET/CT time-points and for a validation cohort. HSV decreased in 64% of patients at W2 and in 80% at W5. CP distinguished earlier disease progression (geographically-dynamic) from later disease progression (geographically-static) in both time-points and cohorts. The texture feature low grey-level zone emphasis predicted local recurrence with AUC(W2) = 0.82 and AUC(W5) = 0.81 in initial cohort (N = 25) and AUC(W2) = 0.79 and AUC(W5) = 0.80 in validation cohort. Radiomics analysis of F-18-FMISO-derived hypoxia dynamics was able to predict outcome of HNSCC patients after CRT.

Published
2021

41. Value of PET imaging for radiation therapy

Author

Lapa, C., Nestle, U., Albert, N., Baues, C., Beer, A., Buck, A., Budach, V., Bütof, R., Combs, S., Derlin, T., Eiber, M., Fendler, W., Furth, C., Gani, C., Gkika, E., Grosu, A., Henkenberens, C., Ilhan, H., Löck, S., Marnitz-Schulze, S., Miederer, M., Mix, M., Nicolay, N., Niyazi, M., Pöttgen, C., Rödel, C., Schatka, I., Schwarzenboeck, S., Todica, A., Weber, W., Wegen, S., Wiegel, T., Zamboglou, C., Zips, D., Zöphel, K., Zschaeck, S., Thorwarth, D., (0000-0001-9550-9050) Troost, E. G. C., Lapa, C., Nestle, U., Albert, N., Baues, C., Beer, A., Buck, A., Budach, V., Bütof, R., Combs, S., Derlin, T., Eiber, M., Fendler, W., Furth, C., Gani, C., Gkika, E., Grosu, A., Henkenberens, C., Ilhan, H., Löck, S., Marnitz-Schulze, S., Miederer, M., Mix, M., Nicolay, N., Niyazi, M., Pöttgen, C., Rödel, C., Schatka, I., Schwarzenboeck, S., Todica, A., Weber, W., Wegen, S., Wiegel, T., Zamboglou, C., Zips, D., Zöphel, K., Zschaeck, S., Thorwarth, D., and (0000-0001-9550-9050) Troost, E. G. C.

Abstract

This comprehensive review written by experts in their field gives an overview on the current status of incorporating positron emission tomography (PET) into radiation treatment planning. Moreover, it highlights ongoing studies for treatment individualisation and per-treatment tumour response monitoring for various primary tumours. Novel tracers and image analysis methods are discussed. The authors believe this contribution to be of crucial value for experts in the field as well as for policy makers deciding on the reimbursement of this powerful imaging modality.

Published
2021

46. Immunohistochemistry and Radiomics Features for Survival Prediction in Small Cell Lung Cancer

Author

Gkika, E., primary, Benndorf, M., additional, Oerther, B., additional, Mohammad, F., additional, Beitinger, S., additional, Adebahr, S., additional, Carles, M., additional, Schimek-Jasch, T., additional, Zamboglou, C., additional, Frye, B.C., additional, Bamberg, F., additional, Waller, C., additional, Grosu, A., additional, Nestle, U., additional, and Kayser, G., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results